Long-term antidepressant treatment with moclobemide for aphasia in acute stroke patients: a randomised, double-blind, placebo-controlled study

↓ Direkt till sidans innehåll
↓ Direkt till sidans sekundära innehåll (sidomenyn)

Sökning: WFRF:(Laska A) > Long-term antidepre...

LIBRIS Formathandbok (Information om MARC21)

Fältnamn	Indikatorer	Metadata
000		02714naa a2200301 4500
001		oai:prod.swepub.kib.ki.se:1937804
003		SwePub
008		240913s2005 \| \|\|\|\|\|\|\|\|\|\|\|000 \|\|eng\|
024	7	a http://kipublications.ki.se/Default.aspx?queryparsed=id:19378042 URI
024	7	a https://doi.org/10.1159/0000832562 DOI
040		a (SwePub)ki
041		a engb eng
042		9 SwePub
072	7	a ref2 swepub-contenttype
072	7	a art2 swepub-publicationtype
100	1	a Laska, ACu Karolinska Institutet4 aut
245	1 0	a Long-term antidepressant treatment with moclobemide for aphasia in acute stroke patients: a randomised, double-blind, placebo-controlled study
264		c 2005-02-03
264	1	b S. Karger AG,c 2005
520		a <i>Background and Purpose:</i> Pharmacotherapy aimed at stroke rehabilitation through direct central nervous effects may be assumed to work in a similar way for language recovery and sensory-motor recovery. Some data suggest that antidepressant drugs could be beneficial also for functional improvement. This prompted us to investigate whether regression from aphasia after acute stroke could be enhanced by antidepressive drug therapy. <i>Methods:</i> We randomised 90 acute stroke patients with aphasia to either 600 mg moclobemide or placebo daily for 6 months, within 3 weeks of the onset of stroke. Aphasia was assessed prior to treatment and at 6 months, using Reinvang’s ‘Grunntest for afasi’ and the Amsterdam-Nijmegen-Everyday-Language-Test (ANELT). <i>Result:</i> The degree of aphasia decreased significantly at 6 months, with no difference between the moclobemide- and the placebo-treated groups. Multivariate regression analysis including treatment group, activities of daily living, aetiology of stroke, ANELT, and Reinvang’s coefficient at baseline, and neurological deficit confirmed these results. In all, 13 in the moclobemide and 10 in the placebo group stopped taking the study medication. No further change was found in the 56 aphasic patients followed up for another 6 months with no medication. <i>Conclusions:</i> Compared to placebo, treatment with moclobemide for 6 months did not enhance the regression of aphasia following an acute stroke.
700	1	a von Arbin, Mu Karolinska Institutet4 aut
700	1	a Kahan, Tu Karolinska Institutet4 aut
700	1	a Hellblom, A4 aut
700	1	a Murray, Vu Karolinska Institutet4 aut
710	2	a Karolinska Institutet4 org
773	0	t Cerebrovascular diseases (Basel, Switzerland)d : S. Karger AGg 19:2, s. 125-132q 19:2<125-132x 1015-9770x 1421-9786
856	4 8	u http://kipublications.ki.se/Default.aspx?queryparsed=id:1937804
856	4 8	u https://doi.org/10.1159/000083256

Hitta via bibliotek

Cerebrovascular diseases (Basel, Switzerland) (Sök värdpublikationen i LIBRIS)

Till lärosätets databas

Hitta mer i SwePub

Av författaren/redakt...: Laska, AC; von Arbin, M; Kahan, T; Hellblom, A; Murray, V

Artiklar i publikationen: Cerebrovascular ...

Av lärosätet: Karolinska Institutet

Sök utanför SwePub

Sök vidare i:: Google; Google Book Search; Google Scholar

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

LIBRIS.kb.se